Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BiTing is a Traditional Chinese Medicine (TCM) pharmaceutical product developed and manufactured by Shanxi Buchang Pharmaceutical. It is primarily indicated for the treatment of nasal and respiratory conditions, including chronic rhinitis, allergic rhinitis, and sinusitis. The formulation is typically available as oral granules and is composed of several botanical extracts, such as *Xanthium sibiricum* (Cang Er Zi), *Magnolia biondii* (Xin Yi), and *Angelica dahurica* (Bai Zhi). These ingredients are traditionally recognized for their anti-inflammatory, analgesic, and decongestant properties, helping to alleviate nasal congestion and sinus pressure. BiTing is an approved drug in China and is part of Buchang Pharmaceutical's extensive portfolio of TCM-based therapies for respiratory health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BiTing.